A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
The report focused on the 5 conditions—multiple sclerosis (MS), immune deficiency, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and chemotherapy—that account for more than 75% of spending on administered drugs.
Changing the setting of administration would save $16,000 to $37,000 per privately insured patient per year, the report said, reflecting a savings opportunity between 33% and 52%.
By condition, the report separated monthly costs by place of administration:
For 2 conditions—RA and IBD—costs were slightly higher when drugs were administered at home versus a provider’s office, but both sites were still far less than hospital settings.
For chemotherapy, the report found a $16,000 savings for 4 months of treatment ($8281 monthly costs for a provider’s office and $12,315 for a hospital setting).
The report comes as the use of specialty drugs is increasing; since 2013, annual growth in per capita spending on administered specialty drugs has averaged 14%. With healthcare costs expected to reach $6 trillion by 2027, policymakers have been grappling with different ideas to try to reverse the trends.
The report said that treating patients at home could add to physical and mental wellbeing, with fewer schedule disruptions related to work or family, without the likelihood of adverse drug events or side effects.
Compared to independent physician offices, hospitals charge more for specialty drugs and their administration, whether treatment occurs in a hospital or in a hospital-owned physician practice.
Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab
January 14th 2025The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Top 5 Most-Read Oncology Articles of 2024
December 24th 2024The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.